ENROLL IN FROM WHERE I STAND TODAY!
Share your story…
about receiving TREANDA and the passions you continue to pursue.
You may have heard of From Where I Stand from your physician. Below is a summary of the program.
We have heard many stories about people with your disease in the past. At Cephalon, Inc. we’re interested in learning about your personal experiences while receiving TREANDA.
The focus of this film would be on your journey from diagnosis through treatment, and how TREANDA played a role in your treatment. We want to know how your disease has directly impacted you and your passions, and how your passions continue to endure.
After enrolling, a representative will contact you to participate in a phone interview to discuss general criteria. If you meet all the necessary criteria and are selected to participate in the film, production will begin based on your schedule. Production will involve you appearing on camera discussing your experiences with TREANDA. Some of these stories may be used in other materials.
Please sign up and begin sharing your story.
ENROLL
Indications
TREANDA is indicated for the treatment of patients with chronic lymphocytic leukemia
(CLL). Efficacy relative to first-line therapies other than chlorambucil has not
been established.
TREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin’s
lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab
or a rituximab-containing regimen.
Important Safety Information
- The most common non-blood-related side effects (occurring in ≥15% of patients) with TREANDA are nausea, fatigue, vomiting, diarrhea, pyrexia (fever), constipation, anorexia (loss of appetite), cough, headache, weight decreased, dyspnea (difficulty breathing), rash, and stomatitis (inflammation of the mouth)
- The most common blood-related side effects (occurring in ≥15% of patients) with TREANDA are reduction of lymphoid cells in the blood, low counts of leukocytes (white blood cells), reduction of red blood cells, reduction of neutrophils (white blood cells) and reduction of blood platelets
- Allergic Reactions: There is a possibility of mild or serious allergic reactions with TREANDA. Immediately report rash, facial swelling, or difficulty breathing during or soon after infusion because these symptoms may become severe or even life-threatening
- Myelosuppression: TREANDA may cause a decrease in white blood cells, platelets, and red blood cells. You will need frequent monitoring of your blood cells. Report shortness of breath, significant fatigue, bleeding, fever, or other signs of infection because these symptoms may become severe or even life-threatening
- Pregnancy and Nursing: TREANDA can cause fetal harm. Women should avoid becoming pregnant throughout treatment and for 3 months after TREANDA therapy has stopped. Men receiving TREANDA should use reliable contraception for the same time period. Report pregnancy immediately. Avoid nursing while receiving TREANDA
- Fatigue: TREANDA may cause tiredness. Avoid driving any vehicle or operating any dangerous tools or machinery if you experience this side effect
- Nausea and Vomiting: TREANDA may cause nausea and/or vomiting. You should report nausea and vomiting to your doctor so that you can get treatment for these symptoms
- Diarrhea: TREANDA may cause diarrhea. You should report diarrhea to your doctor so that it can be treated
- Rash: A mild rash or itching may occur during treatment with TREANDA. Immediately report severe or worsening rash or itching to your doctor
- Some side effects may lead to the dose of TREANDA being lowered, stopped, or delayed
- You should not take TREANDA if you have a known allergy to bendamustine or mannitol